Dr. Benjamin N. Lockshin, MD

Medicare patients and services

Medicare patients, 2024

1,257

Services billed

5,735

Patients’ average age

77

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 741 payments worth $758,149 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Maryland →

Industry-funded research

Named as a principal investigator on 19 industry-funded studies in 2025, from 8 companies. The companies reported $390,517 in research payments for these studies, mostly to the institutions running them.

• A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
  Pfizer Inc.
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
  Eli Lilly and Company · Recruiting · NCT05723198
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
  Eli Lilly and Company · Completed · NCT06588283
• A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
  Eli Lilly and Company · Completed · NCT05369403
• A phase 4, prospective, open-label, single arm study to assess the effectiveness of tirzepatide after initiation of ixekizumab in adult participants with moderate-to-severe plaque psoriasis and obesity or overweight i…
  Eli Lilly and Company
• Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
  Regeneron Pharmaceuticals, Inc. · Completed · NCT05590585
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06585410
• A phase 3 external and synthetic placebocontrolled randomized study with doseup for nonresponders to investigate safety and efficacy of ritlecitinib 50 mg and 100 mg once daily in adult and adolescent participants 12 …
  Pfizer Inc.
• A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK)
  E.r. Squibb & Sons, L.l.c.
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
  Incyte Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Silver Spring

• Vivien Y. Chen
• Amy B. Cole, MD
• Edward W. Cowen, M.D.
• Eleanor Y. Ford, MD
• Kavita Goyal, M.D.
• Mary E. Kim, M.D.
• Michelle M. Levender, MD
• Norman A. Lockshin, MD